Survey shows dismal ICD-10 readiness

More than half of healthcare organizations are not yet ready for the Oct. 1 ICD-10 transition, according to a new survey.

Conducted by Porter Research and commissioned by Navicure, a billing and payments services vendor, the survey collected the opinions of billers and coders; practice administrators or billing managers; and practice executives.

Two-thirds (67 percent) were from small practices with between one and 10 providers.

According to the survey, 85 percent of respondents expect to be ready for the transition by Oct. 1 but 57 percent said they are not currently ready.

Thirty-one percent of respondents named clinical documentation improvement and coding requirements as the most challenging aspects of the transition while 56 percent of respondents cited cash flow disruptions as their greatest concern. However, 35 percent reported that they had not adjusted their revenue cycle in preparation for the transition.

Respondents also said they are concerned about negative effects on patient experience and staff productivity.

More than one-third (35 percent) of respondents had not yet conducted any end-to-end testing and, among those who had completed end-to-end testing, 60 percent reported positive results.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.